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1. Introduction 
The eye’s uveal tract consists of the iris, ciliary body, and choroid. It contains a population 
of melanocytes. Uveal melanomas develop from melanocytes that reside within the stroma 
of the choroid, ciliary body or iris. 
The choroid is the vascular part of the human eye between retina and sclera. Though 
accurate measurements of the choroidal blood flow is difficult, it is known that choroid is 
one of the most vascular tissues in the body and its blood flow is one of highest (1). It is a 
feared condition because it is potentially lethal and the treatment of metastatic melanoma is 
ineffective. 
2. Epidemiology 
Uveal melanomas are found  in 3% of cases in the iris, in  5–10%  of cases in the ciliary body 
and in 90% of cases in the choroid in about 40% of cases within 3 mm of optic disc and/or 
fovea. 
Metastatic tumors of the choroid are the most common intraocular malignancy but they are 
only slightly more common than choroidal melanoma. Choroidal melanoma is the most 
common primary intraocular malignancy in adults. It has an estimated annual incidence in 
the United states of 6 cases permillion people (2). Before the age 50 it has an incidence of 3 
per million people and after the age 50 it reaches to 21 per million people (3). Sixty five 
percent of patients are above the age 50 (4). There is no sex predominance. Choroidal 
melanoma is typically unilateral and unifocal (1). Whites are eight times more likely to have 
melanoma than African-Americans and three times more likely than Asians. Most 
melanomas arise from pre-existing, benign choroidal nevi. The prevalence of nevi is 1-2% 
and the incidence of malignant degeneration into melanoma is less than 1% (5). Exposure to 
sunlight has been implicated in the development of iris melanomas but there is no 
convincing evidence to show that sunlight causes choroidal melanomas. Pregnancy 
accelerates the growth of existing melanoma perhaps through endocrine factors such as 
excess melanocyte-stimulating hormone (6). Exposure to UV light or other agents is not a 
risk factor for choroidal melanoma (7).  
The most common predisposing factor for choroidal melanoma is ocular melanositosis. Still 
in congenital ocular melanocytosis the incidence of choroidal melanoma does not exceed %5 
(8). In the white population a lifetime risk of developing uveal melanoma increases from 1 in 
13000 to 1 in 400 when there is an underlying congenital melanocytosis (9).  
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3. Diagnosis 
Mostly the patients are asymptomatic and the tumor is discovered on ophthalmic 
examination. On ophthalmoscopy choroidal melanoma usually present as dome shaped 
tumor with variable pigmentation and sometimes with serous detachment. Tumors are 
generally pigmented but one fourth are relatively non-pigmented or amelanotic (Figure 1). 
Symptomatic patients have may have distorted and/or reduced vision when the tumor 
develops next to or in the macula. Vision field defects may occur  due to exudative 
detachment or corresponding to the tumor. Exudative retinal detachments are usually seen 
with tumors more that 4 mm thick. Flashes floaters or photosias may occur due to retinal 
pathology. Pain is rare but occur when there is angle closure or neovascular glaucoma. 
 
 
Fig. 1. An amelonocytic choroidal melanoma of the posterior pole 
An examination consisting of indirect ophthalmoscopy, fluorescein angiography, scleral 
transillumination, b-scan ultrasonography has a diagnostic accuracy rate of 99.7% as 
reported by the Collaborative Ocular Melanoma Study (COMS) (10). In the same study an 
examination with indirect ophthalmoscopy, revealing a choroidal tumor with orange 
pigment on its surface and subretinal fluid is correctly diagnosed as choroidal melanoma in 
99.6% of cases (10). 
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Flourescein angiography is reported to have a diagnostic accuracy rate of %36.6 (11). Early 
hypofluorescence is seen in pigmented melanomas and late hyperfluorescent areas can be 
seen depending on the interaction of the tumor with the retina pigment epithelium. With 
changes in RPE early dot-like areas of hyperfluorescence become prominent and they 
increase in intensity in late phases. Fluorescein angiography may also reveal a typical 
double circulation seen in choroidal melanomas, a characteristic image caused by 
simultaneusly retinal and tumor circulation. 
For tumors greater than 3 mm thick a combined A-mode and B-mode ultrasonography is 
more than 95% accurate in diagnosing choroidal melanoma. B-mode ultrasonography might 
reveal a typical acoustically silent zone within the melanoma, choroidal excavation and 
acoustic shadowing of the orbit. With A-mode medium to low internal reflectivity might be 
seen. 
Fine needle biopsy is usually not suggested for seeding of the needle tract is reported (12, 
13).  
4. Prognosis 
Long-term follow-up reveals that eventually more than 50% of patients die of disseminated 
disease (14). About 30-50% of patients with choroidal melanoma will die within 10 years 
from diagnosis and treatment. As found in the Collaborative Ocular Melanoma Study, for 
large melanomas the 10-year rates of death secondary to metastasis  are 45% in pre-
enucleation radiation and 40% and in the enucleation alone treatment groups (10). 
It is usually secondary to distant metastases, and the risk is greatest in larger tumors.  
Though at presentation only 1-3 % of patients have detectable metastases. Overt metastases 
are fatal and if untreated median survival time is 2-6 months (15, 16). If treated survival time 
prolongs only up to 12-15 months (17).  
 
Study Small Size Medium Size Large Size 
Meta-analysis 1966-
1988 a 
<3mm height 
<10mm diameter 
10-15 mm diameter >15 mm diameter 
 <10 mm diameter 10-15 mm diameter 
>15 mm diameter or 
>5 mm height 
 <11 mm diameter 11-15 mm diameter  
 < 300mm2 <15 mm diameter  
COMS 1,5-2,4 mm height 2,5-10 mm heightb >10 apical height 
 5-16 mm diameter <16 mm diameter >16 mm diameter 
a Included 8 studies with overlapping size criteria 
b Changed November 1990 3,1 to 8,0 mm. 
Table 1. Definition of size in choroidal melanomas* 
                                                 
* Cancer Control 2004 H.Lee Moffitt Cancer Center and Research Institute, Inc. 
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Commonly accepted clinical risk factors are larger size of the tumor, anterior location, 
proximity to the foveal avascular zone, advanced patient age and histopathology (Table 1). 
Especially the character of specific vascular abnormalities such as vascular networks, closed 
loops, and parallel-with-cross-linking microcirculation-related patterns appear to predict 
tumors more likely to metastasize (18). 
 
 
Small Size 
Melanoma 
Mortality 
Medium Size 
Melanoma 
Mortality 
Large Size 
Melanoma 
Mortality 
Meta analysis 16% 32% 53% 
5-year all cause 
(COMS) 
16 % 
19% a 
18% b 
43% a 
38% b 
5-year tumor 
related (COMS) 
1% 
11% a 
9% b 
28% a 
26% b 
 
(Helsinky Study) a 
 
 
All sizes 
 
4 year tumor 
related mortality 
 31%  
15 year tumor 
related mortality 
 45%  
25 year tumor 
related mortality 
 49%  
35 year tumor 
related mortality 
 52%  
a enucleation alone 
b enucleation with preoperative radiation 
Table 2. Mortality rates of choroidal melanoma* 
5. Treatment 
Treatment modalities for choroidal melanoma are brachytherapy,The Collaborative Ocular 
Melanoma Study (COMS) is a multicenter investigation designed to evaluate therapeutic 
interventions for patients who have choroidal melanoma. This study aimed to find out 
which one of the treatment modalities would prolong the remaining lifetime and which of 
them would have better prognosis for vision overall. There are several treatment modalities: 
a) Observation 
If the diagnosis is not definite, the lesion should be followed with fundus photography and 
ultrasound. Factors that differentiate a choroidal melanoma from choroidal nevi are 
                                                 
* Cancer Control 2004 H.Lee Moffitt Cancer Center and Research Institute, Inc. 
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thickness (>2mm), subretinal fluid, symptoms, orange pigment and a lesion margin that is 
touching to optic disc.  
Observation as a management choice is a situation where: 
1. The ophthalmologist has detected a presumably melanocytic choroidal tumor that is 
either a relatively large but benign choroidal nevus or a small but malignant choroidal 
melanoma, 
2. That he or she has informed the patient of the findings and differential diagnosis, 
3. That he or she has recommended comprehensive reevaluation of the suspicious tumor 
on a periodic basis (at intervals to be determined on a case-by-case basis by the 
ophthalmologist, depending on his or her level of concern about the lesion's "prior 
probability" of being a true malignant melanoma), and 
4. That he or she had indicated to the patient that some form of intervention is likely to be 
recommended when a particular threshold of change in the lesion has been identified 
(19). 
b) Transpupillary Thermotherapy 
In the mid-1990s the initial observations of Transpupillary Thermotherapy (TTT) for small 
choroidal melanoma reported successful with minimal side effects (20), but its popularity 
later waned following documented recurrences (21, 22). 
In TTT light in the infrared range (810 nm) is delivered trough a modified slit-lamp. The 
long wavelenght passes through ocular tissues and it is absorbed by melanin which is found 
in high concentration in choroidal melanomas. The tumor is heated up to 60°C  and causes 
tissue necrosis. It is preferred when the lesion is under 2 mm thick but a growth in size is 
documented. It has also been used for tumors up to 4 mm in thickness (23-25), preferably 
coupled with brachytherapy treating the tumor base. In 1998 Shields et al. reported the 
results of the largest published case series of TTT for choroidal melanoma with 100 patients. 
After a mean of three treatment sessions and 14 months of follow-up, tumor control was 
successful in 94 of 100 eyes. The remaining 6 eyes were classified as treatment failures. Four 
of these eyes showed partial or no response to thermotherapy, thus requiring plaque 
radiotherapy or enucleation and two eyes showed recurrence, but subsequently controlled 
with additional thermotherapy. The most frequent ocular side-effects in that series included 
vascular obstruction in 23% and retinal traction in 20% of patients, which occurred within a 
mean time interval of 4–5 months after TTT. 
TTT offers great advantages over enucleation or radiation. Because light can be focused 
easyly, TTT causes minimal callateral damage and therefore it does not cause cataract, optic 
neuropathy or retinopathy and visual outcome following TTT may be outstanding. 
c) Charged particle Irradiation and Plaque Brachytherapy 
Radiotherapy may be a vision-sparing alternative to enucleation for patients with choroidal 
melanoma. The most commonly used forms of radiotherapy are ophthalmic plaque 
brachytherapy and charged-particle (external beam) radiotherapy.  
External beam irradiation of melanomas with charged particles, protons or helium nuclei, 
has been performed since 1975. 
Plaque radiotherapy or charged-particle radiation is particularly recommended for medium 
or small sized uveal melanoma which are not suitable to TTT. In CMOS study eyes of 
patients with tumors from 2.5 mm to 10 mm in apical height and basal diameter of 16 mm or 
less are treated with a radioactive plaque if randomized to radiation. 
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The tumor control rate after plaque or charged-particle radiotherapy appears to be similar 
but charged-particle irradiation may produce worse anterior-segment complications than 
plaque radiotherapy (26, 27). Currently 125I radiation therapy is considered excellent for 
intraocular tumors because since it lacks alpha or beta rays, its penetrance allows the 
treatment of large tumors and the seeds are commercially available and can be reused. Only 
125I  is used in CMOS study.  
The local recurrence rate of melanomas treated with 125I plaques is 4% (28). After all forms of 
radiotherapy many patients experience sight-limiting side effects due to optic neuritis and 
an average of 16.3% of patients treated with radiotherapy subsequently require enucleation 
because of tumor regrowth or uncontrollable neovascular glaucoma. 
d) Enucleation 
Until the 1980's, the standard treatment of choroidal melanoma was the removal of the eye 
by enucleation (29). Enucleation is still performed for large uveal melanoma when there is 
no hope of regaining useful vision but based on the published literature, it seems that 
enucleation carries the same survival prognosis as each of the conservative treatment 
modalities. According to CMOS study mortality rates following 125I brachytherapy does not 
differ from those following enucleation through 12 years follow-up time. 
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